Competitive CYP2C9 inhibitors:: Enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis

被引:98
作者
Afzelius, L
Zamora, I
Ridderström, M
Andersson, TB
Karlén, A
Masimirembwa, CM [1 ]
机构
[1] AstraZeneca R&D, Dept DMPK & Bioanalyt Chem, S-43183 Molndal, Sweden
[2] Uppsala Univ, Biomed Ctr, Dept Organ Pharmaceut Chem, Uppsala, Sweden
关键词
D O I
10.1124/mol.59.4.909
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
This study describes the generation of a three-dimensional quantitative structure activity relationship (3D-QSAR) model for 29 structurally diverse, competitive CYP2C9 inhibitors defined experimentally from an initial data set of 73 compounds. In parallel, a homology model for CYP2C9 using the rabbit CYP2C5 coordinates was built. For molecules with a known interaction mode with CYP2C9, this homology model, in combination with the docking program GOLD, was used to select conformers to use in the 3D-QSAR analysis. The remaining molecules were docked, and the GRID interaction energies for all conformers proposed by GOLD were calculated. This was followed by a principal component analysis (PCA) of the GRID energies for all conformers of all compounds. Based on the similarity in the PCA plot to the inhibitors with a known interaction mode, the conformer to be used in the 3D-QSAR analysis was selected. The compounds were randomly divided into two groups, the training data set (n = 21) to build the model and the external validation set (n = 8). The PLS (partial least-squares) analysis of the interaction energies against the K-i values generated a model with r(2) = 0.947 and a cross-validation of q(2) = 0.730. The model was able to predict the entire external data set within 0.5 log units of the experimental K-i values. The amino acids in the active site showed complementary features to the grid interaction energies in the 3D-QSAR model and were also in agreement with mutagenesis studies.
引用
收藏
页码:909 / 919
页数:11
相关论文
共 47 条
[1]
Bapiro TE, 2001, DRUG METAB DISPOS, V29, P30
[2]
EVALUATION OF MODEL DISCRIMINATION, PARAMETER-ESTIMATION AND GOODNESS-OF-FIT IN NONLINEAR-REGRESSION PROBLEMS BY TEST STATISTICS DISTRIBUTIONS [J].
BARDSLEY, WG ;
BUKHARI, NAJ ;
FERGUSON, MWJ ;
CACHAZA, JA ;
BURGUILLO, FJ .
COMPUTERS & CHEMISTRY, 1995, 19 (02) :75-84
[3]
GENERATING OPTIMAL LINEAR PLS ESTIMATIONS (GOLPE) - AN ADVANCED CHEMOMETRIC TOOL FOR HANDLING 3D-QSAR PROBLEMS [J].
BARONI, M ;
COSTANTINO, G ;
CRUCIANI, G ;
RIGANELLI, D ;
VALIGI, R ;
CLEMENTI, S .
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS, 1993, 12 (01) :9-20
[4]
D-OPTIMAL DESIGNS IN QSAR [J].
BARONI, M ;
CLEMENTI, S ;
CRUCIANI, G ;
KETTANEHWOLD, N ;
WOLD, S .
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS, 1993, 12 (03) :225-231
[5]
Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples [J].
Boobis, AR ;
McKillop, D ;
Robinson, DT ;
Adams, DA ;
McCormick, DJ .
XENOBIOTICA, 1998, 28 (05) :493-506
[6]
A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6 [J].
de Groot, MJ ;
Ackland, MJ ;
Horne, VA ;
Alex, AA ;
Jones, BC .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (20) :4062-4070
[7]
Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6 [J].
de Groot, MJ ;
Ackland, MJ ;
Horne, VA ;
Alex, AA ;
Jones, BC .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (09) :1515-1524
[8]
Domanski TL, 2000, J PHARMACOL EXP THER, V293, P585
[9]
Ekins S, 2000, DRUG METAB DISPOS, V28, P994
[10]
Ekins S, 1999, J PHARMACOL EXP THER, V288, P21